Novel NMDA-targeted Therapy for Alzheimer's Disease

Information

  • Research Project
  • 8714993
  • ApplicationId
    8714993
  • Core Project Number
    R43AG047709
  • Full Project Number
    1R43AG047709-01
  • Serial Number
    047709
  • FOA Number
    PA-13-234
  • Sub Project Id
  • Project Start Date
    8/15/2014 - 10 years ago
  • Project End Date
    7/31/2016 - 8 years ago
  • Program Officer Name
    REFOLO, LORENZO
  • Budget Start Date
    8/15/2014 - 10 years ago
  • Budget End Date
    7/31/2016 - 8 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/11/2014 - 10 years ago
Organizations

Novel NMDA-targeted Therapy for Alzheimer's Disease

Abstract Memantine, an aminoadamantane, is approved to treat moderate-to-severe Alzheimer's disease in the US and in Europe. Memantine selectively inhibits abnormally active N-methyl-D-aspartate-type glutamate receptor (NMDAR) channels, while preserving normal glutamate activity and physiological neuronal function (Lipton, 2006; Lipton, 2007a,b). Pathological NMDA receptor activity is further down-regulated by Snitrosylation of cysteine residues located on the N-terminus or extracellular domain. Taking advantage of these insights, PRI has developed a proprietary series of bifunctional antagonists, called nitromemantines, that not only preferentially bind to the open-channel state but also selectively target NO to a second modulatory site using the memantine pharmacophore as a homing motif (Wang, 2006, Wang et al. patents). Our data suggest that some of these memantine analogs have good potency, while maintaining selectivity for persistently open NMDAR channels. Most importantly, they appear to have greater neuroprotective properties than memantine in both in vitro and in vivo animal models. Recent work from the laboratory of our collaborator and co-inventor, Professor Stuart Lipton (Burnham Institute) demonstrates the unique ability of one of our nitromemantines (YQW-036, 1-amino-3,5-diethyl-7-nitrateadamantane) to rescue/protect synapses perhaps by superior inhibition of pathogenic extrasynaptic NMDARs (Talantova, 2013) This animal POC combined with the demonstrated safety of nitromemantines support the translation of this basic science work into clinical stage evaluation. Hence, our overall goal is to initiate preclinical studies to support submission of an IND for YQW-036. This effort will begin with Phase I pharmacokinetics and safety studies of YQW-036 as a potential development candidate. Successful completion of the Phase I studies will merit submission of a Phase II application to support IND enabling studies that are required prior to human clinical trials. Successful achievement of these milestones will provide a proprietary first-in-class disease-modifying drug for Alzheimer's disease.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R43
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224667
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:224667\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PANORAMA RESEARCH, INC.
  • Organization Department
  • Organization DUNS
    556962439
  • Organization City
    SUNNYVALE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940891202
  • Organization District
    UNITED STATES